RNAC
RNAC
NASDAQ · Biotechnology

Cartesian Therapeutics Inc

$10.42
+0.78 (+8.09%)
As of Jun 30, 10:27 PM ET ·
Financial Highlights (FY 2026)
Revenue
3.08M
Net Income
-143,547,561
Gross Margin
Profit Margin
-4,658.6%
Rev Growth
-70.7%
D/E Ratio
0.28
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 60.3% 60.3%
Operating Margin -5,127.1% -4,614.4% 2.7% 2.7%
Profit Margin -4,658.6% -4,425.7% 2.6% 2.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.08M 10.50M 132.93M 135.85M
Gross Profit 80.14M 81.90M
Operating Income -157,999,789 -484,661,929 3.54M 3.60M
Net Income -143,547,561 -440,329,941 3.48M 3.56M
Gross Margin 60.3% 60.3%
Operating Margin -5,127.1% -4,614.4% 2.7% 2.7%
Profit Margin -4,658.6% -4,425.7% 2.6% 2.6%
Rev Growth -70.7% -70.7% -1.8% +9.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 28.72M 28.72M 76.99M 61.16M
Total Equity 102.61M 102.61M 89.31M 77.96M
D/E Ratio 0.28 0.28 0.86 0.78
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -154,721,083 -500,971,468 5.52M 5.23M
Free Cash Flow 2.68M 1.65M